CD274 and neoplasm: Therapeutic monoclonal antibodies (mAb) that interrupt inhibitory immune checkpoint signalling (such as the interaction of PD-1 with its ligand PD-L1) to tumour-infiltrating lymphocytes (TILs) have been shown to successfully trigger an anti-tumour immune response (Figure 1).